Cygnus gains development grants for GlucoWatch:
This article was originally published in Clinica
Executive Summary
Cygnus has received two grants worth a total of $200,000 from the US National Institutes of Health to support the development of its noninvasive, automatic glucose monitoring system, the GlucoWatch Biographer. The first grant will be used to develop a method for predicting hypoglycaemic events, while the second will focus on using a predictive kinetic method to reduce the effects of certain variables on results obtained with the Biographer. The FDA granted Redwood City, California-based Cygnus an approvable letter for its GlucoWatch in May.